Abstract:Keiichi Kubota Department of Surgery, Tohto Bunkyo Hospital, Tokyo, Japan Comment on: Barros AZA, Fonseca GM, Kruger JAP, et al . Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications? J Gastrointest Oncol 2022;13:3123-34. Keywords: Hepatic resection; indication criteria; Barcelona Clinic Liver Cancer prognosis and treatment strategy guideline (BCLC guideline); hepatocellular carcinoma (HCC) Submitted Nov 28, 2022. Accepted for publication Jul 31, 2023. Published online Aug 30, 2023. doi: 10.21037/jgo-2022-03 There have been major advances in the treatment for hepatocellular carcinoma (HCC). Firstly, I congratulate the authors on the excellent achievements of surgical treatment for HCC patients (1). Really, it is not easy to treat HCC patients. Many factors including number and size of HCC, liver function, portal vein invasion and presence or absence of liver cirrhosis may affect the treatment selection among hepatic resection, radio frequency ablation, transcatheter arterial embolization, systemic therapy and transplantation. In this complex situation, the Barcelona Clinic Liver Cancer prognosis and treatment strategy (BCLC) guideline is used for deciding a treatment option for HCC patients in many countries (2-4). Although BCLC guideline enables to standardize treatment allocation for HCC patients, for us surgeons, it still seems to restrict indications of hepatic resection to selective patients. The authors insisted that many reports from Eastern and European centers are less dogmatic and restrictive regarding the indications for HCC resection unlike the BCLC guidelines, since many patients with large tumors, nodules less than 3 nodules, or regional portal vein tumor invasion may benefit from resection. Then in this paper, the authors discussed the results of surgical treatment indicated by more liberal indication than proposed by the BCLC guidelines 2010 and 2018, in which hepatic resection was indicated only to patients with single nodule (withdrawal of the 5-cm tumor size limit for resection in 2018 BCLC). To be more concrete, the authors applied hepatic resection to patients with nodules less than 3 nodules, portal invasion to the first-, second- and third-order branch, and no significant portal hypertension. They compared overall survival (OS) and disease-free survival (DFS) after resection in patients with none, one, two or three of the main risk factors, including portal hypertension, portal system invasion, and presence of more than one HCC nodule, which were proposed by the BCLC criteria in 2010 as contraindications to resection (2,3). Multivariate analysis demonstrated that independent risk factors for OS were portal hypertension, the presence of more than one HCC, or satellite nodules on imaging examinations. Independent risk factors for DFS were increased alpha-fetoprotein levels and more than one HCC nodule. Nodule size and presence of portal invasion alone did not affect OS and DFS. Furthermore, they showed that there was no significant difference between the survival of patients resected in accordance with BCLC 2010 and from those resected, but that BCLC would have contraindicated surgery. While analysis of the OS and DFS curves demonstrated that patients who underwent resection in accordance with BCLC 2018 guidelines had higher OS and DFS than those in whom the BCLC guidelines would have contraindicated resection. Finally, they concluded that selected patients with one BCLC contraindication factor may undergo resection with good results, whereas those with two factors should be allocated for hepatectomy only in favorable scenarios. Patients with the three risk factors do not appear to benefit from resection. These recommendations sound reasonable. In this paper, the value of serum alpha-fetoprotein (AFP) level was not fully discussed, but C-reactive protein (CRP) and AFP levels were reported to be associated with prognosis (5). The value of tumor marker should be further evaluated for selecting treatment option and prognosticating HCC patients. In Japan, ICG retention rate at 15 minutes is used for selecting indication of surgery for patients with the number less than 3 nodules (6). Portal hypertension and portal system invasion are not criteria for contraindicating surgery. In my routine practice, when a platelet count is less than 60,000/mL, splenectomy is performed, resulting in an increase of platelet, then followed by hepatic resection. I do not discuss whether this treatment strategy is justified or not. I just agree with the authors on the point that hepatic resection for patients with one or two contraindication criteria of BCLC guidelines may benefit such patients. Updated BCLC guidelines 2022 is still restrictive against surgery (7). It is obvious that extension of surgical indication to HCC -Abstract Truncated-

The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review

Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification

Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification

Expanded Criteria for Resection: Are Current Guidelines Too Conservative?

Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis

Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications?

Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis

Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm

Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

Can indication of hepatic resection for hepatocellular carcinoma patients be expanded?

Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines

Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization—A Meta-Analysis

Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: A systematic review and meta-analysis

Prognostic impact of liver resection side in peri-hilar cholangiocarcinoma: A systematic review and meta-analysis

Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number

Liver transplantation and BCLC classification: Limitations impede optimum treatment

Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma

Liver transplantation vs liver resection in HCC: promoting extensive collaborative research through a survival meta-analysis of meta-analyses

Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival.